Findings report that the FASN inhibition response can be measured through the basal levels of pAMPK and pAkt, and FASN inhibitors can have a potential effect either in the treatment of early CRC, or as prevention therapy (Cruz et al., 2014; Yekaterina et al., 2016; Drury et al., 2022). Here, FASN is linked to colorectal carcinoma.